Janet D. Siliciano

Nov 28, 2024 | cell.com | Milica Moskovljevic |Filippo Dragoni |Nathan L. Board |Fengting Wu |Jun S. Lai |Hao Zhang | +10 more

Keywords HIV-1 persistence HIV-1 latent reservoir latency reversal antigenic stimulation dendritic cells CD4+ T cells cytomegalovirus Introduction Antiretroviral therapy (ART) effectively blocks viral replication, but HIV-1 persists in a small pool of latently infected resting CD4+ T cells harboring inducible, replication-competent proviruses.1,2,3 This reservoir was originally characterized with a quantitative viral outgrowth assay (QVOA) in which resting CD4+ T cells are stimulated with...

Feb 15, 2024 | science.org | Janet D. Siliciano |Robert F. Siliciano

PerspectiveMedicineCure strategies are confounded by basic reservoir biologyJanet D. Siliciano and Robert F. Siliciano [email protected] Info & AffiliationsCombination antiretroviral therapy (ART) for HIV-1 infection reduces plasma virus levels such that clinical assays for viremia are negative. Because of unexpected cooperativity in dose-response relationships and drug synergies, ART completely inhibits new infection events, halting viral evolution and disease progression (1).

Feb 14, 2024 | sciencemag.org | Pankaj Sharma |Jie Chen |Yu Yang |Janet D. Siliciano

PerspectiveMedicineCure strategies are confounded by basic reservoir biologyCombination antiretroviral therapy (ART) for HIV-1 infection reduces plasma virus levels such that clinical assays for viremia are negative. Because of unexpected cooperativity in dose-response relationships and drug synergies, ART completely inhibits new infection events, halting viral evolution and disease progression (1).

Jan 26, 2024 | nature.com | Nathan L. Board |Milica Moskovljevic |Francesco Simonetti |Janet D. Siliciano |Luis Montaner |Sung Soo Mun

AbstractThe persistence of CD4+ T cells carrying latent human immunodeficiency virus-1 (HIV-1) proviruses is the main barrier to a cure. New therapeutics to enhance HIV-1-specific immune responses and clear infected cells will probably be necessary to achieve reduction of the latent reservoir. In the present study, we report two single-chain diabodies (scDbs) that target the HIV-1 envelope protein (Env) and the human type III Fcγ receptor (CD16).